Zacks Research Has Pessimistic View of Amgen Q3 Earnings

Key Points

• Zacks Research has lowered its Q3 2025 earnings per share estimate for Amgen from $5.32 to $4.89, while the full-year earnings consensus is set at $20.62 per share.
• Amgen's stock currently has a consensus rating of "Hold" with an average price target of $304.43, and the company has declared a quarterly dividend of $2.38 to be paid in September.
• Despite the downgraded earnings outlook, some analysts maintain positive projections, including an "outperform" rating from William Blair and a target price increase from Mizuho to $280.00.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Equities research analysts at Zacks Research cut their Q3 2025 EPS estimates for shares of Amgen in a research note issued to investors on Tuesday, August 26th. Zacks Research analyst Team now forecasts that the medical research company will earn $4.89 per share for the quarter, down from their prior estimate of $5.32. The consensus estimate for Amgen's current full-year earnings is $20.62 per share. Zacks Research also issued estimates for Amgen's Q4 2025 earnings at $4.99 EPS, FY2025 earnings at $20.80 EPS, Q2 2026 earnings at $5.25 EPS, Q4 2026 earnings at $5.47 EPS, Q1 2027 earnings at $5.03 EPS, Q2 2027 earnings at $5.57 EPS and FY2027 earnings at $21.88 EPS.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. The business had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business's revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.

AMGN has been the topic of several other research reports. Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Bank of America raised their price target on Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a report on Wednesday, July 23rd. William Blair restated an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $305.00 target price on shares of Amgen in a research report on Tuesday, June 24th. Finally, Mizuho boosted their price target on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Amgen has a consensus rating of "Hold" and an average price target of $304.43.

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $0.95 on Friday, reaching $286.76. 929,259 shares of the company's stock were exchanged, compared to its average volume of 2,792,624. The business's 50-day moving average is $293.44 and its two-hundred day moving average is $292.85. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $339.17. The firm has a market capitalization of $154.38 billion, a price-to-earnings ratio of 23.45, a PEG ratio of 2.50 and a beta of 0.49.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.3%. Amgen's dividend payout ratio (DPR) is presently 77.84%.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 1,267 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares of the company's stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Wealth Preservation Advisors LLC bought a new position in shares of Amgen during the 1st quarter valued at about $25,000. Pinney & Scofield Inc. bought a new stake in Amgen during the fourth quarter worth approximately $26,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the second quarter worth approximately $27,000. First Pacific Financial grew its position in Amgen by 304.5% in the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after buying an additional 67 shares during the last quarter. Finally, CBIZ Investment Advisory Services LLC increased its holdings in shares of Amgen by 1,214.3% in the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock valued at $29,000 after buying an additional 85 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.